NASDAQ:ATRI

Atrium Therapeutics Stock Climbs: The Key FDA Filing Investors Are Watching Now
····

Atrium Therapeutics Stock Climbs: The Key FDA Filing Investors Are Watching Now

Atrium Therapeutics shares climbed 1.9% to $12.96 Thursday, valuing the company at about $222 million. The RNA drug developer expects to submit its first IND for ATR 1072, targeting PRKAG2 syndrome, in the second half of 2026. Atrium reported $267.8 million in cash at March 31, with all programs still preclinical. Leerink Partners initiated coverage last week with an outperform rating and $25 price target.
May 21, 2026

Stock Market Today

  • Xero Shares Plunge 62% Amid Tech Sell-Off, Analysts Bullish on 87% Upside
    May 29, 2026, 8:21 PM EDT. Xero Ltd (ASX: XRO) shares have fallen 62% from a $196.52 peak in June 2025, pressured by a broader tech sector sell-off linked to AI disruption fears and prior overvaluation concerns. Currently trading at $74.16, Xero is down 34% year-to-date. Despite recent losses, 14 of 15 analysts rate Xero shares a buy or strong buy, with an average 12-month target price implying a 76% gain to $130.81, and some forecasts projecting up to 218% upside. The company's recurring subscription revenue offers predictable cash flow, underpinned by high customer retention from accounting and payroll services. Growth prospects include expansion in the UK and US markets, automation enhancements, and product suite diversification. Recent FY26 results underscore 31% revenue growth and 18% EBITDA increase, reinforcing long-term investment appeal.